Morgan Stanley's Equal-Weight Rating on Humana Amid Concerns
Morgan Stanley Maintains Equal-Weight Rating on Humana
Morgan Stanley has recently reaffirmed an Equal-weight rating for Humana (NYSE: HUM) while setting a price target of $374.00 per share. This comes in light of concerning news regarding a decline in the number of members enrolled in 4+ Stars plans, as reported by the Centers for Medicare & Medicaid Services (CMS).
Significant Decline in 4+ Stars Enrollment
Humana announced that only about 1.6 million members, which equates to 25% of its total enrollment, will qualify for 4+ Stars plans. This marks a dramatic drop from 94% that was observed previously. The major contributor to this decline stems from the company's largest contract, identified as H5216, experiencing a decrease in rating from 4.5 Stars to 3.5 Stars.
Analyst Insights and Future Implications
The analysts at Morgan Stanley expressed concern, noting that this significant shift in enrollment was unexpected, raising questions regarding Humana's short-term outlook. They estimate that this change could impact earnings per share (EPS) for 2026 by approximately 90%, primarily due to the reduced affiliation with the higher Star-rated plans. In response, Humana has indicated its intention to evaluate potential strategies to alleviate the expected revenue challenges associated with the new 2025 Star ratings.
Review of CMS Data and Company Appeals
In reviewing CMS' preliminary data, Humana's management observed that the reduction in Star ratings might be linked to narrowly missing the higher industry benchmarks across several evaluation measures. The company has taken action, filing appeals with CMS, believing that there may be errors in the initial calculations.
Anticipated Results and Future Revenue Challenges
The complete results from CMS are set to be disclosed soon. Humana is also actively working on various strategies to address anticipated revenue impacts for 2026, acknowledging that its goal to achieve a Medicare Advantage margin of at least 3% by 2027 is now more uncertain than previously thought.
Comparative Analysis with Competitors
Furthermore, the analyst pointed out potential implications for other health companies, such as CVS Health (NYSE: CVS). It has been observed that CVS Health's key contracts seem to be performing better, which could benefit the company in a challenging market.
Current Standing of CVS Health
As indicated on the PlanFinder website, two of CVS' largest contracts are currently rated at 4.5/4 Stars and account for approximately 57% of their members, maintaining their status as 4+ Stars plans. The analysts postulate that should CVS experience a slight decrease in ratings, the anticipated impact on their 2026 EPS might be limited, around $0.13, translating to approximately 1.6%.
Understanding Humana's Market Position
Recent insights from market analysis provide a broader context for Humana’s situation. The company’s market capitalization is currently valued at about $28.87 billion with a P/E ratio of 16.36. This lower P/E ratio, alongside Humana's trading at a relatively modest revenue multiple, implies that the market may already be reflecting the worries around the recent drop in Star ratings.
Share Buybacks and Dividend History
InvestingPro notes that Humana has been actively repurchasing shares and has successfully maintained dividend payments for an impressive 14 consecutive years. These efforts are indicative of the management's confidence in the company's long-term viability, notwithstanding present challenges. Nonetheless, the stock has faced a notable downturn, with a month-to-date total return of -20.95% and a year-to-date decline of -38.48%.
Market Outlook and Profitability Predictions
Despite the setbacks, analysts are optimistic that Humana will maintain profitability within the current year. This aligns with the company’s strategies to manage the repercussions stemming from the drop in Star ratings on its revenue for 2026. For those interested in a more in-depth analysis, further insights are available, shedding light on Humana's financial standing and market dynamics.
Frequently Asked Questions
What rating did Morgan Stanley give Humana?
Morgan Stanley maintained an Equal-weight rating on Humana with a price target of $374.00.
What has caused the decline in Humana's Star ratings?
The decline is primarily due to Humana's largest contract falling from 4.5 Stars to 3.5 Stars according to the latest CMS assessment.
How does this affect Humana's earnings?
The expected impact on Humana's earnings per share for 2026 is approximately 90%, potentially leading to significant revenue challenges.
What steps is Humana taking in response to the ratings drop?
Humana is exploring various strategies to mitigate the expected revenue headwinds caused by the new Star ratings.
How does CVS Health compare in this situation?
CVS Health appears to be performing better with its key contracts, which may provide a more stable outlook compared to Humana's recent challenges.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Toyota Unveils Major Investment to Propel Joby Aviation Forward
- Challenges Ahead: Fed's Barkin on Persistent Inflation Tensions
- Legal Battle: States Challenge FCC's Inmate Phone Call Regulations
- Exploring October Trends: Will Bitcoin Shine This Month?
- Class Action Alert: Important Details for STMicroelectronics Investors
- Understanding the Upcoming Class Action for Stellantis Stockholders
- Lululemon Investors: Critical Class Action Filing Deadline Soon
- NANO Nuclear Energy Inc. Faces Legal Action for Shareholder Rights
- Investors Alert: Class Action Against Starbucks Corporation
- Oil Markets React to Middle East Tensions Amid Global Disruption
Recent Articles
- First Watch Restaurant Group Faces Market Challenges
- Forge Global Holdings Faces Market Challenges as Stock Dips
- WTW Partners with J. Morey Company to Enhance Risk Solutions
- Colombia's Inflation Forecast Shows Signs of Easing in September
- Omada Health Takes Significant Step Towards IPO with S-1 Filing
- Nikola Achieves Record Truck Sales, But What’s Next?
- Bill Gates Proposes a Tax System to Reshape Wealth in America
- Soniquence Enhances RF Technology Support for Ellman Devices
- Billy Ocean Returns to Enchant Fans at Pittsburgh's Casino
- Act Now: Join the Class Action Against Moderna, Inc. MRNA
- Innovative AI-Driven Price Watch Solution Unveiled by Procurant
- Protect Your Rights as a GitLab Inc. Shareholder Now
- Historic Construction Milestone for Fisher House at Lovell FHCC
- Join the Class Action Against Endava plc (DAVA) Today
- Upcoming Q&A Webcast on Disney's Financial Performance
- Growth of Dental Diamond Bur Market Driven by Innovation and Demand
- Important Investor Information Regarding Coinbase Lawsuit Timelines
- Earls Restaurant Group Announces Exciting Nashville Expansion
- Emerging Therapies Redefining SERD Market Dynamics for Growth
- Legal Action Against XPEL, Inc.: What Investors Need to Know
- Important Notice for Shareholders of Verve Therapeutics, Inc.
- WTW Teams Up With The J. Morey Company for Enhanced Solutions
- Untether AI and Ampere Team Up for Energy-Efficient AI Solutions
- Class Action Encouragement for Ford Motor Company Investors
- Joseph Marullo Joins 401GO as Chief of Staff to Drive Growth
- Important Steps for AGEN Shareholders: Know Your Rights
- LaSalle Vaughn Becomes Chief Compliance Officer at Altruist
- Key Insights on the Class Action Against Super Micro Computer, Inc.
- OdysseyRe Appoints Daniel Boisvert as Senior VP in Property Treaty
- Exploring Intuitive Machines' Strategic NASA Contract Impact
- Nissan Foundation Opens Grant Cycle for Diverse Nonprofits
- Exploring RTX's New DARPA Contract for Semiconductor Innovations
- Lenders Cooperative Enhances SBA Lending with Expert Chuck Evans
- Geopolitical Risks Threaten Global Markets: Insights from BoE
- Apple's iPhone 16 Drives Growth Amid Shifting Preferences
- Toyota's Major Investment in Joby Aviation Boosts Electric Air Taxis
- Innovative Uber and Accommodations Plus Partnership Enhances Travel Efficiency
- BTM Industrial to Auction General Motors Surplus Assets Soon
- Montrose Environmental Group's Stock Faces Market Challenges
- Vegas Golden Knights App Launches With Everi's Innovative Tech
- HSBC Upgrades Daqo New Energy: A Bright Future Ahead
- Piera Systems' Innovative Vape Detectors Gain Provincial Support
- Ducommun Achieves New Heights: A Deep Dive into Growth
- Ford's Growth in Hybrid and EV Markets: A Solid Future Ahead
- Innovative Vehicle-to-Grid Technology Shines at Exelon Showcase
- Shutterstock Faces Market Struggles Amid New Opportunities
- Stellantis Celebrates 25 Years of Supplier Diversity Success
- Hershey's Stock Price Surge: Implications of Mars Price Increases
- KEY's Natural Energy Drink: A Game Changer in Retail Growth
- Marcus Corporation Reaches New Heights with Stock Surge